Skip to main content

Table 1 Patient attributes

From: The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis

 

Mean ± SD

 

Age (year)

55.6 ± 9.7

 
 

n

%

Stage

 1

7

36.8

 2

6

31.6

 3

4

21.1

 4

2

10.5

TNM classification

 T1, N0, M0

8

42.1

 T2, N0, M0

3

15.8

 T2, N1, M0

2

10.5

 T4, N0, M0

2

10.5

 T4, N2, M0

2

10.5

 T4, N0, M1

2

10.5

PS

  

 0

19

100.0

HER2

 3+

7

36.8

 2+

1

5.3

 1+

7

36.8

 (−)

4

21.1

ER

 (+)

13

68.4

 (−)

3

15.8

 (±)

3

15.8

PgR

 (+)

12

63.2

 (−)

3

15.8

 (±)

4

21.1

Purpose of chemotherapy

 Adjuvant

7

36.8

 Neoadjuvant

11

57.9

 Symptom relief

1

5.3

Regimen

 EC (every 3w)

8

42.1

 TRZ + nabPTX (every 3w)

3

15.8

 TC (every 3w)

2

10.5

 3w-nabPTX (every 3w)

3

15.8

 LPR (every 4w)

3

15.8

Marital status

 Married

14

73.7

 Unmarried

5

26.3

Cohabitants

 Yes

19

100.0

 No

0

0.0

Current occupation

 Temporary employment, part-time employment

10

52.6

 Company employee, self-employed

6

31.6

 Public official

0

0.0

 Other

3

15.8

Current annual income

 0–999,999 yen

10

52.6

 1,000,000–4,999,999 yen

7

36.8

 5,000,000–9,999,999 yen

2

10.5

 10,000,000– yen

0

0.0

Occupation before diagnosis

 Temporary employment, part-time employment

10

52.6

 Company employee, self-employed

6

31.6

 Public official

0

0.0

 Other

3

15.8

Education

 Junior school graduate

3

15.8

 High school graduate

7

36.8

 Vocational school, junior college, technical school graduate

8

42.1

 University graduate, postgraduate

1

5.3

Experience as a healthcare professional

 Currently a healthcare professional

0

0.0

 Was a healthcare professional in the past

1

5.3

 Was not a healthcare professional in the past

18

94.7

  1. SD standard deviation, PS performance status, HER2 human epidermal growth factor receptor type 2, ER estrogen receptor, PgR progesterone receptor, EC epirubicin/cyclophosphamide, TC docetaxel/cyclophosphamide, TRZ trastuzumab, LPR leuprorelin, nabPTX nab-paclitaxel, 3w 3 weeks, 4w 4 weeks